| scholarly article | Q13442814 |
| P2093 | author name string | Chris Mason | |
| David A Brindley | |||
| Emily J Culme-Seymour | |||
| Brock C Reeve | |||
| Natasha L Davie | |||
| William A Sahlman | |||
| Greg A Bonfiglio | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 397-401 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Cell Stem Cell | Q2943975 |
| P1476 | title | The impact of market volatility on the cell therapy industry | |
| P478 | volume | 9 |
| Q33837051 | An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol |
| Q35739401 | Challenges in the translation and commercialization of cell therapies |
| Q48380662 | Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation |
| Q36751585 | Enabling stem cell therapies for tissue repair: current and future challenges |
| Q39393419 | Global competencies of regional stem cell research: bibliometrics for investigating and forecasting research trends |
| Q26751188 | In silico regenerative medicine: how computational tools allow regulatory and financial challenges to be addressed in a volatile market |
| Q58314420 | News Commentary: Human embryonic stem cell therapy in the post-Geron era |
| Q37968318 | Peak serum: implications of serum supply for cell therapy manufacturing |
| Q53180436 | Stem cell based therapy--where are we going? |
| Q64900938 | Stem cell biomanufacturing under uncertainty: A case study in optimizing red blood cell production. |
| Q84390579 | Tissue-engineered vascular replacements for children |
Search more.